Opinion|Videos|January 10, 2025
Transplant-Ineligible Myeloma and MRD Integration: Current Definitions and Future Directions
Author(s)Saad Z. Usmani, MD, MBA, FACP, FASCO
Saad Z. Usmani, MD, MBA, FACP, discusses how the definition of the transplant-ineligible population for multiple myeloma is evolving while also addressing the challenges of standardizing minimal residual disease (MRD) as a biomarker across various treatment settings and clinical trials to ensure consistent and reliable use in treatment decision-making.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What, in your opinion, is the definition of the transplant-ineligible population for multiple myeloma?
- With the growing use of MRD as a biomarker, what challenges remain in standardizing its use across different treatment settings and trials?
Advertisement
Related to this article
Systematic review finds combined immunonutrition (arginine, omega-3s, glutamine) in colorectal cancer surgery may cut surgical site infections, while single supplements show no benefit.
FACT Accreditation lets Tennessee Oncology bring community oncology CAR T-cell therapy closer to home, expanding access for non-Hodgkin lymphoma patients.
The analysis found a nonlinear association between systemic inflammation and overactive bladder, with stronger links at higher inflammation levels.
A real-world study found that adding a GLP-1 to SGLT2 inhibitor therapy was associated with lower kidney, cardiovascular, and mortality risks in CKD.
In experiments at MD Anderson, rising CD70 helps mantle cell lymphoma evade immunity; a CD70×CD3 bispecific restores T-cell killing and prolongs survival in resistant models.
The NPS index, ranging from –100 to +100, serves as a proxy for customers’ willingness to recommend products and services they themselves have used.
North Carolina experts discussed CLL, breast cancer, and myeloma treatments and how to expand access to complex cancer care beyond academic centers.
The IRA's Medicare out-of-pocket cap is easing costs for patients with cancer, but community oncology leaders warn price cuts are straining practices.
Advertisement
Advertisement
Trending on AJMC
1
Tavapadon for Parkinson Disease Approved by FDA
2
Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices
3
Access and Innovation in North Carolina’s Research Triangle
4
Biomarker-Driven Care Is Racing Ahead of the Systems Built to Support It
5